Clinical Trial Update: A Phase I Safety and Pharmacokinetics Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Infants and Children With AIDS or Symptomatic HIV Infection [Phase 1]

View source ↗

Summary

Phase I safety and pharmacokinetics study of didanosine (2',3'-dideoxyinosine) given twice daily to infants and children with HIV infection or AIDS; study statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Videx (didanosine) (didanosine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED